Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

Perfusion Process Intensification for Lentivirus Production Using a Novel Scale‐Down Model

Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line

Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing

Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines

Exploring nutrient supplementation and bioprocess optimization to improve the production of lentiviral vectors in serum‐free medium suspension cultures

Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration

Continuous Manufacturing of Lentiviral Vectors using a Stable Producer Cell Line in a Fixed-Bed Bioreactor

High yield sterile filtration process for highly concentrated lentiviral vectors

Fed‐batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

Advances in Lentivirus Purification

Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid process

The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process

Development of a laboratory scalable process for enhancing lentivirus production by transient transfection of HEK293 adherent cultures

Ex Vivo Machine Perfusion as a Platform for Lentiviral Gene Delivery in Rat Livers

Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration

Scaleable purification process for gene therapy retroviral vectors

Process Intensification by Inoculating Antibody Production Bioreactors Directly from Cryovials

Development of a high‐throughput scale‐down model in Ambr® 250 HT for plasmid DNA fermentation processes